Stockreport

Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi

Opiant Pharmaceuticals, Inc.  (OPNT) 
Last opiant pharmaceuticals, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.opiant.com/investor-overview
PDF SANTA MONICA, Calif., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addict [Read more]